CA2846460C - Aprepitant l-proline composition and cocrystal - Google Patents
Aprepitant l-proline composition and cocrystal Download PDFInfo
- Publication number
- CA2846460C CA2846460C CA2846460A CA2846460A CA2846460C CA 2846460 C CA2846460 C CA 2846460C CA 2846460 A CA2846460 A CA 2846460A CA 2846460 A CA2846460 A CA 2846460A CA 2846460 C CA2846460 C CA 2846460C
- Authority
- CA
- Canada
- Prior art keywords
- aprepitant
- cocrystal
- proline
- disease
- itch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38574410P | 2010-09-23 | 2010-09-23 | |
| US61/385,744 | 2010-09-23 | ||
| US201161439654P | 2011-02-04 | 2011-02-04 | |
| US61/439,654 | 2011-02-04 | ||
| US201161498214P | 2011-06-17 | 2011-06-17 | |
| US61/498,214 | 2011-06-17 | ||
| PCT/IB2011/054210 WO2012038937A1 (en) | 2010-09-23 | 2011-09-23 | Aprepitant l-proline composition and cocrystal |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2846460A1 CA2846460A1 (en) | 2012-03-29 |
| CA2846460C true CA2846460C (en) | 2019-01-08 |
Family
ID=44907915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2846460A Active CA2846460C (en) | 2010-09-23 | 2011-09-23 | Aprepitant l-proline composition and cocrystal |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9029369B2 (OSRAM) |
| EP (1) | EP2618828B1 (OSRAM) |
| JP (1) | JP5997162B2 (OSRAM) |
| KR (1) | KR101833578B1 (OSRAM) |
| CN (1) | CN103221049B (OSRAM) |
| AR (1) | AR083095A1 (OSRAM) |
| AU (1) | AU2011306391B2 (OSRAM) |
| BR (1) | BR112013006651A2 (OSRAM) |
| CA (1) | CA2846460C (OSRAM) |
| ES (1) | ES2616752T3 (OSRAM) |
| IL (1) | IL225443A0 (OSRAM) |
| TW (1) | TWI540131B (OSRAM) |
| WO (1) | WO2012038937A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011306391B2 (en) | 2010-09-23 | 2016-12-15 | Nuformix Limited | Aprepitant L-proline composition and cocrystal |
| CN104159584A (zh) * | 2011-11-25 | 2014-11-19 | 诺弗米克斯有限公司 | 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体 |
| US10098859B2 (en) | 2012-09-05 | 2018-10-16 | Amri Ssci, Llc | Cocrystals of p-coumaric acid |
| WO2015101596A2 (en) * | 2013-12-30 | 2015-07-09 | Oncoprevent Gmbh | Neurokinin-1 receptor antagonists for use in a method of prevention of cancer |
| JP2021512910A (ja) | 2018-02-07 | 2021-05-20 | リアタ ファーマシューティカルズ インコーポレイテッド | ノボビオシン類似体とプロリンとの共結晶形態 |
| CN116283947A (zh) * | 2023-02-07 | 2023-06-23 | 成都医学院 | 一种阿瑞匹坦共晶及其制备方法和用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US6048859A (en) | 1992-06-29 | 2000-04-11 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| US5719147A (en) | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| ZA985765B (en) | 1997-07-02 | 1999-08-04 | Merck & Co Inc | Polymorphic form of a tachykinin receptor antagonist. |
| US20050025791A1 (en) * | 2002-06-21 | 2005-02-03 | Julius Remenar | Pharmaceutical compositions with improved dissolution |
| EP1608339B8 (en) * | 2003-02-28 | 2012-04-25 | McNeill-PPC, Inc. | Pharmaceutical co-crystal of celecoxib-nicotinamide |
| US20090209541A1 (en) * | 2006-06-16 | 2009-08-20 | Dr. Reddy's Laboratories Ltd. | Aprepitant compositions |
| US20110009362A1 (en) * | 2008-02-27 | 2011-01-13 | Dr. Reddy's Laboratories Ltd. | Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof |
| AU2011306391B2 (en) | 2010-09-23 | 2016-12-15 | Nuformix Limited | Aprepitant L-proline composition and cocrystal |
-
2011
- 2011-09-23 AU AU2011306391A patent/AU2011306391B2/en active Active
- 2011-09-23 CN CN201180055997.5A patent/CN103221049B/zh active Active
- 2011-09-23 ES ES11779217.6T patent/ES2616752T3/es active Active
- 2011-09-23 US US13/825,380 patent/US9029369B2/en active Active
- 2011-09-23 AR ARP110103486 patent/AR083095A1/es unknown
- 2011-09-23 BR BR112013006651A patent/BR112013006651A2/pt not_active Application Discontinuation
- 2011-09-23 CA CA2846460A patent/CA2846460C/en active Active
- 2011-09-23 JP JP2013529758A patent/JP5997162B2/ja active Active
- 2011-09-23 WO PCT/IB2011/054210 patent/WO2012038937A1/en not_active Ceased
- 2011-09-23 KR KR1020137010228A patent/KR101833578B1/ko active Active
- 2011-09-23 TW TW100134362A patent/TWI540131B/zh active
- 2011-09-23 EP EP11779217.6A patent/EP2618828B1/en active Active
-
2013
- 2013-03-21 IL IL225443A patent/IL225443A0/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL225443A0 (en) | 2013-06-27 |
| US20130252949A1 (en) | 2013-09-26 |
| EP2618828B1 (en) | 2016-11-23 |
| AU2011306391A1 (en) | 2013-04-11 |
| HK1187554A1 (zh) | 2014-04-11 |
| EP2618828A1 (en) | 2013-07-31 |
| CN103221049A (zh) | 2013-07-24 |
| TW201217366A (en) | 2012-05-01 |
| JP5997162B2 (ja) | 2016-09-28 |
| KR20140040671A (ko) | 2014-04-03 |
| US9029369B2 (en) | 2015-05-12 |
| CN103221049B (zh) | 2015-11-25 |
| AR083095A1 (es) | 2013-01-30 |
| AU2011306391B2 (en) | 2016-12-15 |
| BR112013006651A2 (pt) | 2017-07-18 |
| TWI540131B (zh) | 2016-07-01 |
| WO2012038937A1 (en) | 2012-03-29 |
| ES2616752T3 (es) | 2017-06-14 |
| JP2013537901A (ja) | 2013-10-07 |
| KR101833578B1 (ko) | 2018-02-28 |
| CA2846460A1 (en) | 2012-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024164208A (ja) | Ｂｔｋ阻害剤の結晶形態 | |
| EP2618828B1 (en) | Aprepitant l-proline composition and cocrystal | |
| CA2892832C (en) | Aprepitant l-proline solvates - compositions and cocrystals | |
| US8779146B2 (en) | Cilostazol cocrystals and compositions | |
| US8871793B2 (en) | Metaxalone cocrystals | |
| AU2022384750B2 (en) | Therapeutic cocrystals of 3-{[5-(azetidine-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-{[(1 s)-1 -methyl-2- (methyloxy)ethyl]oxy)-n-(5-methylpyrazin-2-yl)benzamide | |
| US11891401B2 (en) | Solid forms of N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide | |
| HK1187554B (en) | Aprepitant l-proline composition and cocrystal | |
| IL324898A (en) | New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinozolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide | |
| HK1178519B (en) | Metaxalone cocrystals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160914 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241122 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241122 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241122 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250919 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250919 |